POZ Platform™
Our proprietary POZ platform technology has been designed for programmable, targeted delivery of a broad range of small molecules. The technology has been clinically demonstrated to safely enable continuous drug delivery via a once weekly subcutaneous injection. The POZ platform is customizable, versatile and can be dosed via IV, SC or IM routes to address a broad range of clinical indications.
Small Molecule Conjugates
We have a pipeline of wholly-owned CNS drug candidates, addressing large markets with significant unmet need.
Lipid Nanoparticles (LNPs)
Our collaborations with partners to advance LNP based drug delivery in mRNA immunology highlights the broad potential of our POZ platform technology.
Antibody-Drugs (ADCs)
POZ enables improved efficacy against Low-Density Targets by Increasing the Drug Antibody Ratio (DAR) of cancer killing cytotoxins.
Join Us.
We’re pioneering bold new science.